GUARANTY AND SECURITY AGREEMENT dated as of July 23, 2018 by and among AERIE PHARMACEUTICALS, INC., a Delaware corporation, as Borrower, the other Grantors and Guarantors party hereto from time to time and Deerfield Private Design Fund III, L.P., as...Guaranty and Security Agreement • July 23rd, 2018 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances)
GUARANTY AND SECURITY AGREEMENT (this “Agreement”) dated as of July 23, 2018 by and among AERIE PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), AERIE DISTRIBUTION, INC., a Delaware corporation (“Aerie Distribution”), each other Person who becomes a party hereto pursuant to Section 8.15 (together with Borrower and Aerie Distribution, the “Grantors” and each, a “Grantor”), each other Person signatory hereto as a “Guarantor” (as defined below) and Deerfield Private Design Fund III, L.P., as Agent.
CREDIT AGREEMENT dated as of July 23, 2018, by and among AERIE PHARMACEUTICALS, INC., as Borrower CERTAIN SUBSIDIARIES OF THE BORROWER, as Guarantors, VARIOUS LENDERS, and DEERFIELD PRIVATE DESIGN FUND III, L.P., as Agent $100,000,000 Subsequent...Credit Agreement • July 23rd, 2018 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT (this “Agreement”), dated as of July 23, 2018, by and among Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the other Loan Parties (as defined below) party hereto from time to time, the lenders set forth on the signature page of this Agreement (together with their successors and assigns, the “Lenders”), Deerfield Private Design Fund III, L.P., as agent for itself and the Lenders (in such capacity, together with its successors and assigns in such capacity, “Agent,” and, together with the Lenders, the Borrower and the other Loan Parties party hereto, the “Parties”).
EXCHANGE AND TERMINATION AGREEMENTExchange and Termination Agreement • July 23rd, 2018 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This EXCHANGE AND TERMINATION AGREEMENT (this “Agreement”) dated as of July 23, 2018, is by and among Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), Deerfield Private Design Fund III, L.P. (“DPD III”), Deerfield Partners, L.P. (“DP”) and Deerfield Special Situations Fund, L.P. (“DSS” and, together with DPD III and DP, the “Purchasers”). The Purchasers and the Borrower are referred to herein collectively as the “Parties.” Capitalized terms used herein which are defined in the Purchase Agreement (as defined below), unless otherwise defined herein, shall have the meanings ascribed to them in the Purchase Agreement.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 23rd, 2018 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 23, 2018, by and among Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Deerfield Private Design Fund III, L.P. (“DPD III”), Deerfield Partners, L.P. (“DP”) and Deerfield Special Situations Fund, L.P. (“DSS” and, together with DPD III and DP, the “Purchasers”). The Purchasers and the Company are referred to herein collectively as the “Parties.” Capitalized terms used herein which are defined in the Exchange Agreement (as defined below), unless otherwise defined herein, shall have the meanings ascribed to them in the Exchange Agreement.
